New anxiety pill shows promise in major trial

NCT ID NCT06741228

Ongoing Symptom relief Sponsor: Definium Therapeutics US, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 31 times

Summary

This study tests an oral medication called MM120 against a placebo in 214 adults with generalized anxiety disorder. The first 12 weeks are double-blind (neither you nor the doctor knows which group you're in), followed by a 40-week period where everyone can receive MM120. The main goal is to see if MM120 reduces anxiety symptoms measured by a standard rating scale.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Adams Clinical Boston

Boston, Massachusetts, 02116, United States
Adams Clinical Bronx

The Bronx, New York, 10461, United States
Adams Clinical Dallas

DeSoto, Texas, 75115, United States
Adams Clinical Harlem

New York, New York, 10029, United States
Adams Clinical Philadelphia

Philadelphia, Pennsylvania, 19104, United States
Adams Clinical Watertown

Watertown, Massachusetts, 02472, United States
Atlanta Center for Medical Research

Atlanta, Georgia, 30331, United States
Austin Clinical Trial Partners

Austin, Texas, 78737, United States
BioBehavioral Research of Austin

Austin, Texas, 78759, United States
Cedar Clinical Research

Draper, Utah, 84020, United States
CenExel iResearch, LLC

Savannah, Georgia, 31405, United States
Cleveland Clinic Lutheran Hospital

Cleveland, Ohio, 44113, United States
Clinical Neuroscience Solutions Inc.

Jacksonville, Florida, 32256, United States
Clinical Neuroscience Solutions, Inc.

Memphis, Tennessee, 38119, United States
Coastal Carolina Research Center

North Charleston, South Carolina, 29405, United States
FutureSearch Trials of Dallas, LLC

Dallas, Texas, 75231, United States
Hassman Research Institute

Marlton, New Jersey, 08053, United States
Inner Space Research

Orem, Utah, 84058, United States
Kadima Neuropsychiatry Institute

La Jolla, California, 92037, United States
Lighthouse Psychiatry

Gilbert, Arizona, 85234, United States
Memory Clinic Inc.

Bennington, Vermont, 05201, United States
Mountain View

Denver, Colorado, 80209, United States
New York State Psychiatric Institute (NYSPI)

New York, New York, 10032, United States
Psychedelic Science Institute

Santa Monica, California, 90404, United States
Scottsdale Research Institute

Scottsdale, Arizona, 85022, United States
Scranton Medical Institute

Moosic, Pennsylvania, 18507, United States
Seattle Neuropsychiatric Treatment Center

Seattle, Washington, 98104, United States
Segal Trials

Lauderhill, Florida, 33319, United States
Spectrum Neuroscience and Treatment Institute

New York, New York, 10021, United States
Summit Headlands LLC

Portland, Oregon, 97210, United States
UCSF Department of Neurology

San Francisco, California, 94158, United States
University of Texas at Austin

Austin, Texas, 78712, United States
Uptown Research Institute

Chicago, Illinois, 60640, United States
iResearch Atlanta

Decatur, Georgia, 30030, United States

Conditions

Explore the condition pages connected to this study.

GENERALIZED ANXIETY DISORDER GENERALIZED ANXIETY DISORDER